Histone deacetylase inhibitors in hematological malignancies and solid tumors

Archives of Pharmacal Research

Volumn 38, Issue 6, 2015, Pages 933-949

  Chun, Pusoon ^a  

^a Inje University   (South Korea)

Author keywords

Angiogenesis; Apoptosis; Cancer; Cell cycle arrest; DNA damage and repair; Histone deacetylase inhibitors

Indexed keywords

BELINOSTAT; DEPSIPEPTIDE; ENTINOSTAT; GIVINOSTAT; HISTONE DEACETYLASE INHIBITOR; MOCETINOSTAT; PANOBINOSTAT; ROMIDEPSIN; VALPROIC ACID; VORINOSTAT; ANTINEOPLASTIC AGENT; HISTONE DEACETYLASE;

ANEMIA; ANGIOGENESIS; ANOREXIA; ANTIANGIOGENIC ACTIVITY; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; ASTHENIA; CELL CYCLE ARREST; CLINICAL DEVELOPMENT PLAN; DIARRHEA; DNA DAMAGE; DNA REPAIR; DRUG DESIGN; DRUG MECHANISM; DRUG SAFETY; DRUG STRUCTURE; FATIGUE; GASTROINTESTINAL DISEASE; GASTROINTESTINAL SYMPTOM; GENE EXPRESSION REGULATION; GRANULOCYTOPENIA; HEMATOLOGIC DISEASE; HEMATOLOGIC MALIGNANCY; HUMAN; IN VITRO STUDY; IN VIVO STUDY; LEUKOPENIA; LYMPHOCYTOPENIA; LYMPHOMA; NAUSEA; NEUTROPENIA; QT PROLONGATION; SOLID TUMOR; THROMBOCYTOPENIA; VOMITING; ANIMAL; CLASSIFICATION; ENZYMOLOGY; HEMATOLOGIC NEOPLASMS; METABOLISM; NEOPLASMS;

ANIMALS; ANTINEOPLASTIC AGENTS; HEMATOLOGIC NEOPLASMS; HISTONE DEACETYLASE INHIBITORS; HISTONE DEACETYLASES; HUMANS; NEOPLASMS;

EID: 84930868061     PISSN: 02536269     EISSN: 19763786     Source Type: Journal    
DOI: 10.1007/s12272-015-0571-1     Document Type: Article

References (159)

1. Adams, H., F.R. Fritzsche, S. Dirnhofer, G. Kristiansen, and A. Tzankov. 2010. Class I histone deacetylases 1, 2 and 3 are highly expressed in classical Hodgkin's lymphoma. Expert Opinion on Therapeutic Targets 14: 577-584.
2. Amann, J.M., J. Nip, D.K. Strom, B. Lutterbach, H. Harada, N. Lenny, J.R. Downing, S. Meyers, and S.W. Hiebert. 2001. ETO, a target of t(8;21) in acute leukemia, makes distinct contacts with multiple histone deacetylases and binds mSin3A through its oligomerization domain. Molecular and Cellular Biology 21: 6470-6483.
3. Ashkenazi, A. 2002. Targeting death and decoy receptors of the tumour-necrosis factor superfamily. Nature Reviews Cancer 2: 420-430.
4. Atsumi, A., A. Tomita, H. Kiyoi, and T. Naoe. 2006. Histone deacetylase 3 (HDAC3) is recruited to target promoters by PML-RARalpha as a component of the N-CoR co-repressor complex to repress transcription in vivo. Biochemical and Biophysical Research Communications 345: 1471-1480.
5. Bagnes, C., P.N. Panchuk, and G. Recondo. 2010. Antineoplastic chemotherapy induced QTc prolongation. Current Drug Safety 5: 93-96.
6. Bakkenist, C.J., and M.B. Kastan. 2003. DNA damage activates ATM through intermolecular autophosphorylation and dimer dissociation. Nature 421: 499-506.
7. Bali, P., M. Pranpat, J. Bradner, M. Balasis, W. Fiskus, F. Guo, K. Rocha, S. Kumaraswamy, S. Boyapalle, P. Atadja, E. Seto, and K. Bhalla. 2005. Inhibition of histone deacetylase 6 acetylates and disrupts the chaperone function of heat shock protein 90: A novel basis for antileukemia activity of histone deacetylase inhibitors. Journal of Biological Chemistry 280: 26729-26734.
8. Bantscheff, M., C. Hopf, M.M. Savitski, A. Dittmann, P. Grandi, A.M. Michon, J. Schlegl, Y. Abraham, I. Becher, G. Bergamini, M. Boesche, M. Delling, B. Dümpelfeld, D. Eberhard, C. Huthmacher, T. Mathieson, D. Poeckel, V. Reader, K. Strunk, G. Sweetman, U. Kruse, G. Neubauer, N.G. Ramsden, and G. Drewes. 2011. Chemoproteomics profiling of HDAC inhibitors reveals selective targeting of HDAC complexes. Nature Biotechnology 29: 255-265.
9. Bates, S.E., D.R. Rosing, T. Fojo, and R.L. Piekarz. 2006. Challenges of evaluating the cardiac effects of anticancer agents. Clinical Cancer Research 12: 3871-3874.
10. Bertos, N.R., A.H. Wang, and X.J. Yang. 2001. Class II histone deacetylases: Structure, function, and regulation. Biochemistry and Cell Biology 79: 243-252.
11. Bertrand, P. 2010. Inside HDAC with HDAC inhibitors. European Journal of Medicinal Chemistry 45: 2095-2116.
12. Blumenschein Jr., G.R., M.S. Kies, V.A. Papadimitrakopoulou, C. Lu, A.J. Kumar, J.L. Ricker, J.H. Chiao, C. Chen, and S.R. Frankel. 2008. Phase II trial of the histone deacetylase inhibitor vorinostat (Zolinza, suberoylanilide hydroxamic acid, SAHA) in patients with recurrent and/or metastatic head and neck cancer. Investigational New Drugs 26: 81-87.
13. Bolden, J.E., M.J. Peart, and R.W. Johnstone. 2006. Anticancer activities of histone deacetylase inhibitors. Nature Reviews Drug Discovery 5: 769-784.
14. Bradley, D., D. Rathkopf, R. Dunn, W.M. Stadler, G. Liu, D.C. Smith, R. Pili, J. Zwiebel, H. Scher, and M. Hussain. 2009. Vorinostat in advanced prostate cancer patients progressing on prior chemotherapy (National Cancer Institute Trial 6862): Trial results and interleukin-6 analysis: A study by the Department of Defense Prostate Cancer Clinical Trial Consortium and University of Chicago Phase 2 Consortium. Cancer 115: 5541-5549.
15. Bradner, J.E., N. West, M.L. Grachan, E.F. Greenberg, S.J. Haggarty, T. Warnow, and R. Mazitschek. 2010. Chemical phylogenetics of histone deacetylases. Nature Chemical Biology 6: 238-243.
16. Burgess, A., A. Ruefli, H. Beamish, R. Warrener, N. Saunders, R. Johnstone, and B. Gabrielli. 2004. Histone deacetylase inhibitors specifically kill nonproliferating tumour cells. Oncogene 23: 6693-6701.
17. Burz, C., I. Berindan-Neagoe, O. Balacescu, and A. Irimie. 2009. Apoptosis in cancer: Key molecular signaling pathways and therapy targets. Acta Oncologica 48: 811-821.
18. Cashen, A., M. Juckett, A. Jumonville, M. Litzow, P.J. Flynn, J. Eckardt, B. LaPlant, K. Laumann, C. Erlichman, and J. DiPersio. 2012. Phase II study of the histone deacetylase inhibitor belinostat (PXD101) for the treatment of myelodysplastic syndrome (MDS). Annals of Hematology 91: 33-38.
19. Cha, T.L., M.J. Chuang, S.T. Wu, G.H. Sun, S.Y. Chang, D.S. Yu, S.M. Huang, S.K. Huan, T.C. Cheng, T.T. Chen, P.L. Fan, and P.W. Hsiao. 2009. Dual degradation of aurora A and B kinases by the histone deacetylase inhibitor LBH589 induces G2-M arrest and apoptosis of renal cancer cells. Clinical Cancer Research 15: 840-850.
20. Chen, L.f., W. Fischle, E. Verdin, and W.C. Greene. 2001. Duration of nuclear NF-kappaB action regulated by reversible acetylation. Science 293: 1653-1657.
21. Chen, C.S., Y.C. Wang, H.C. Yang, P.H. Huang, S.K. Kulp, C.C. Yang, Y.S. Lu, S. Matsuyama, C.Y. Chen, and C.S. Chen. 2007. Histone deacetylase inhibitors sensitize prostate cancer cells to agents that produce DNA double-strand breaks by targeting Ku70 acetylation. Cancer Research 67: 5318-5327.
22. ClinicalTrials.gov. BELIEF study. http://clinicaltrials.gov/show/NCT00865969. Accessed 21 Nov 2014.
23. Coiffier, B., B. Pro, H.M. Prince, F. Foss, L. Sokol, M. Greenwood, D. Caballero, P. Borchmann, F. Morschhauser, M. Wilhelm, L. Pinter-Brown, S. Padmanabhan, A. Shustov, J. Nichols, S. Carroll, J. Balser, B. Balser, and S. Horwitz. 2012. Results from a pivotal, open-label, phase II study of romidepsin in relapsed or refractory peripheral T-cell lymphoma after prior systemic therapy. Journal of Clinical Oncology 30: 631-636.
24. Curran, M.E., I. Splawski, K.W. Timothy, G.M. Vincent, E.D. Green, and M.T. Keating. 1995. A molecular basis for cardiac arrhythmia: HERG mutations cause long QT syndrome. Cell 80: 795-803.
25. de Ruijter, A.J., A.H. van Gennip, H.N. Caron, S. Kemp, and A.B. van Kuilenburg. 2003. Histone deacetylases (HDACs): Characterization of the classical HDAC family. Biochemical Journal 370: 737-749.
26. Decroos, C., C.M. Bowman, J.A. Moser, K.E. Christianson, M.A. Deardorff, and D.W. Christianson. 2014. Compromised structure and function of HDAC8 mutants identified in Cornelia de Lange Syndrome spectrum disorders. ACS Chemical Biology 9: 2157-2164.
27. Deubzer, H.E., M.C. Schier, I. Oehme, M. Lodrini, B. Haendler, A. Sommer, and O. Witt. 2013. HDAC11 is a novel drug target in carcinomas. International Journal of Cancer 132: 2200-2208.
28. Drugs@FDA. http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm. Accessed 21 Nov 2014.
29. Duvic, M., R. Talpur, X. Ni, C. Zhang, P. Hazarika, C. Kelly, J.H. Chiao, J.F. Reilly, J.L. Ricker, V.M. Richon, and S.R. Frankel. 2006. Phase 2 trial of oral vorinostat (suberoylanilide hydroxamic acid, SAHA) for refractory cutaneous T-cell lymphoma (CTCL). Blood 109: 31-39.
30. El-Khoury, V., S. Pierson, E. Szwarcbart, N.H. Brons, O. Roland, S. Cherrier-De Wilde, L. Plawny, E. Van Dyck, and G. Berchem. 2014. Disruption of autophagy by the histone deacetylase inhibitor MGCD0103 and its therapeutic implication in B-cell chronic lymphocytic leukemia. Leukemia 28: 1636-1646.
31. Fath, D.M., X. Kong, D. Liang, Z. Lin, A. Chou, Y. Jiang, J. Fang, J. Caro, and N. Sang. 2006. Histone deacetylase inhibitors repress the transactivation potential of hypoxia-inducible factors independently of direct acetylation of HIF-alpha. Journal of Biological Chemistry 281: 13612-13619.
32. Feng, G.W., L.D. Dong, W.J. Shang, X.L. Pang, J.F. Li, L. Liu, and Y. Wang. 2014. HDAC5 promotes cell proliferation in human hepatocellular carcinoma by up-regulating Six1 expression. European Review for Medical and Pharmacological Sciences 18: 811-816.
33. Firestein, R., G. Blander, S. Michan, P. Oberdoerffer, S. Ogino, J. Campbell, A. Bhimavarapu, S. Luikenhuis, R. de Cabo, C. Fuchs, W.C. Hahn, L.P. Guarente, and D.A. Sinclair. 2008. The SIRT1 deacetylase suppresses intestinal tumorigenesis and colon cancer growth. PLoS ONE 3: e2020.
34. Fischle, W., V. Kiermer, F. Dequiedt, and E. Verdin. 2001. The emerging role of class II histone deacetylases. Biochemistry and Cell Biology 79: 337-348.
35. Foss, F., R. Advani, M. Duvic, K.B. Hymes, T. Intragumtornchai, A. Lekhakula, O. Shpilberg, A. Lerner, R.J. Belt, E.D. Jacobsen, G. Laurent, D. Ben-Yehuda, M. Beylot-Barry, U. Hillen, P. Knoblauch, G. Bhat, S. Chawla, L.F. Allen, and B. Pohlman. 2014. A Phase II trial of Belinostat (PXD101) in patients with relapsed or refractory peripheral or cutaneous T-cell lymphoma (Abstract). British Journal of Haematology. doi: 10.1111/bjh.13222.
36. Fournel, M., C. Bonfils, Y. Hou, P.T. Yan, M.C. Trachy-Bourget, A. Kalita, J. Liu, A.H. Lu, N.Z. Zhou, M.F. Robert, J. Gillespie, J.J. Wang, H. Ste-Croix, J. Rahil, S. Lefebvre, O. Moradei, D. Delorme, A.R. Macleod, J.M. Besterman, and Z. Li. 2008. MGCD0103, a novel isotype-selective histone deacetylase inhibitor, has broad spectrum antitumor activity in vitro and in vivo. Molecular Cancer Therapeutics 7: 759-768.
37. Fraga, M.F., E. Ballestar, A. Villar-Garea, M. Boix-Chornet, J. Espada, G. Schotta, T. Bonaldi, C. Haydon, S. Ropero, K. Petrie, N.G. Iyer, A. Pérez-Rosado, E. Calvo, J.A. Lopez, A. Cano, M.J. Calasanz, D. Colomer, M.A. Piris, N. Ahn, A. Imhof, C. Caldas, T. Jenuwein, and M. Esteller. 2005. Loss of acetylation at Lys16 and trimethylation at Lys20 of histone H4 is a common hallmark of human cancer. Nature Genetics 37: 391-400.
38. Fritzsche, F.R., W. Weichert, A. Roske, V. Gekeler, T. Beckers, C. Stephan, K. Jung, K. Scholman, C. Denkert, M. Dietel, and G. Kristiansen. 2008. Class I histone deacetylases 1, 2 and 3 are highly expressed in renal cell cancer. BMC Cancer 8: 381.
39. Furumai, R., A. Matsuyama, N. Kobashi, K.H. Lee, M. Nishiyama, H. Nakajima, A. Tanaka, Y. Komatsu, N. Nishino, M. Yoshida, and S. Horinouchi. 2002. FK228 (depsipeptide) as a natural prodrug that inhibits class I histone deacetylases. Cancer Research 62: 4916-4921.
40. Gao, L., M.A. Cueto, F. Asselbergs, and P. Atadja. 2002. Cloning and functional characterization of HDAC11, a novel member of the human histone deacetylase family. Journal of Biological Chemistry 277: 25748-25755.
41. Garcia-Manero, G., H. Yang, C. Bueso-Ramos, A. Ferrajoli, J. Cortes, W.G. Wierda, S. Faderl, C. Koller, G. Morris, G. Rosner, A. Loboda, V.R. Fantin, S.S. Randolph, J.S. Hardwick, J.F. Reilly, C. Chen, J.L. Ricker, J.P. Secrist, V.M. Richon, S.R. Frankel, and H.M. Kantarjian. 2008. Phase 1 study of the histone deacetylase inhibitor vorinostat (suberoylanilide hydroxamic acid [SAHA]) in patients with advanced leukemias and myelodysplastic syndromes. Blood 111: 1060-1066.
42. Gaughan, L., I.R. Logan, S. Cook, D.E. Neal, and C.N. Robson. 2002. Tip60 and histone deacetylase 1 regulate androgen receptor activity through changes to the acetylation status of the receptor. Journal of Biological Chemistry 277: 25904-25913.
43. Gelmetti, V., J.S. Zhang, M. Fanelli, S. Minucci, P.G. Pelicci, and M.A. Lazar. 1998. Aberrant recruitment of the nuclear receptor corepressor-histone deacetylase complex by the acute myeloid leukemia fusion partner ETO. Molecular and Cellular Biology 18: 7185-7191.
44. Geng, L., K.C. Cuneo, A. Fu, T. Tu, P.W. Atadja, and D.E. Hallahan. 2006. Histone deacetylase (HDAC) inhibitor LBH589 increases duration of gamma-H2AX foci and confines HDAC4 to the cytoplasm in irradiated non-small cell lung cancer. Cancer Research 66: 11298-11304.
45. Giaccone, G., A. Rajan, A. Berman, R.J. Kelly, E. Szabo, A. Lopez-Chavez, J. Trepel, M.J. Lee, L. Cao, I. Espinoza-Delgado, J. Spittler, and P.J. Loehrer Sr. 2011. Phase II study of belinostat in patients with recurrent or refractory advanced thymic epithelial tumors. Journal of Clinical Oncology 29: 2052-2059.
46. Gobinet, J., S. Carascossa, V. Cavaillès, F. Vignon, J.C. Nicolas, and S. Jalaguier. 2005. SHP represses transcriptional activity via recruitment of histone deacetylases. Biochemistry 44: 6312-6320.
47. Gregoretti, I.V., Y.M. Lee, and H.V. Goodson. 2004. Molecular evolution of the histone deacetylase family: Functional implications of phylogenetic analysis. Journal of Molecular Biology 338: 17-31.
48. Grunstein, M. 1997. Histone acetylation in chromatin structure and transcription. Nature 389: 349-352.
49. Gui, C.Y., L. Ngo, W.S. Xu, V.M. Richon, and P.A. Marks. 2004. Histone deacetylase (HDAC) inhibitor activation of p21WAF1 involves changes in promoter-associated proteins, including HDAC1. Proceedings of the National Academy of Sciences of USA 101: 1241-1246.
50. Haigentz Jr., M., M. Kim, C. Sarta, J. Lin, R.S. Keresztes, B. Culliney, A.G. Gaba, R.V. Smith, G.I. Shapiro, L.R. Chirieac, J.M. Mariadason, T.J. Belbin, J.M. Greally, J.J. Wright, and R.I. Haddad. 2012. Phase II trial of the histone deacetylase inhibitor romidepsin in patients with recurrent/metastatic head and neck cancer. Oral Oncology 48: 1281-1288.
51. Halkidou, K., L. Gaughan, S. Cook, H.Y. Leung, D.E. Neal, and C.N. Robson. 2004. Upregulation and nuclear recruitment of HDAC1 in hormone refractory prostate cancer. Prostate 59: 177-189.
52. Hayashi, A., A. Horiuchi, N. Kikuchi, T. Hayashi, C. Fuseya, A. Suzuki, I. Konishi, and T. Shiozawa. 2010. Type-specific roles of histone deacetylase (HDAC) overexpression in ovarian carcinoma: HDAC1 enhances cell proliferation and HDAC3 stimulates cell migration with downregulation of E-cadherin. International Journal of Cancer 127: 1332-1346.
53. Heltweg, B., T. Gatbonton, A.D. Schuler, J. Posakony, H. Li, S. Goehle, R. Kollipara, R.A. Depinho, Y. Gu, J.A. Simon, and A. Bedalov. 2006. Antitumor activity of a small-molecule inhibitor of human silent information regulator 2 enzymes. Cancer Research 66: 4368-4377.
54. Hitomi, T., Y. Matsuzaki, T. Yokota, Y. Takaoka, and T. Sakai. 2003. p15(INK4b) in HDAC inhibitor-induced growth arrest. FEBS Letters 554: 347-350.
55. Hörlein, A.J., A.M. Näär, T. Heinzel, J. Torchia, B. Gloss, R. Kurokawa, A. Ryan, Y. Kamei, M. Söderström, C.K. Glass, and M.G. Rosenfeld. 1995. Ligand-independent repression by the thyroid hormone receptor mediated by a nuclear receptor co-repressor. Nature 377: 397-404.
56. Hu, E., E. Dul, C.M. Sung, Z. Chen, R. Kirkpatrick, G.F. Zhang, K. Johanson, R. Liu, A. Lago, G. Hofmann, R. Macarron, M. de los Frailes, P. Perez, J. Krawiec, J. Winkler, and M. Jaye. 2003. Identification of novel isoform-selective inhibitors within class I histone deacetylases. Journal of Pharmacology and Experimental Therapeutics 307: 720-728.
57. Hutt, D.M., D.M. Roth, H. Vignaud, C. Cullin, and M. Bouchecareilh. 2014. The histone deacetylase inhibitor, Vorinostat, represses hypoxia inducible factor 1 alpha expression through translational inhibition. PLoS ONE 9: e106224.
58. Insinga, A., S. Monestiroli, S. Ronzoni, V. Gelmetti, F. Marchesi, A. Viale, L. Altucci, C. Nervi, S. Minucci, and P.G. Pelicci. 2005. Inhibitors of histone deacetylases induce tumor-selective apoptosis through activation of the death receptor pathway. Nature Medicine 11: 71-76.
59. Iwamoto, F.M., K.R. Lamborn, J.G. Kuhn, P.Y. Wen, W.K. Yung, M.R. Gilbert, S.M. Chang, F.S. Lieberman, M.D. Prados, and H.A. Fine. 2011. A phase I/II trial of the histone deacetylase inhibitor romidepsin for adults with recurrent malignant glioma: North American Brain Tumor Consortium Study 03-03. Neurooncology 13: 509-516.
60. Jin, Y.H., E.J. Jeon, Q.L. Li, Y.H. Lee, J.K. Choi, W.J. Kim, K.Y. Lee, and S.C. Bae. 2004. Transforming growth factor-beta stimulates p300-dependent RUNX3 acetylation, which inhibits ubiquitination-mediated degradation. Journal of Biological Chemistry 279: 29409-29417.
61. Johnstone, R.W. 2002. Histone-deacetylase inhibitors: Novel drugs for the treatment of cancer. Nature Reviews Drug Discovery 1: 287-299.
62. Jung, K.H., J.H. Noh, J.K. Kim, J.W. Eun, H.J. Bae, H.J. Xie, Y.G. Chang, M.G. Kim, H. Park, J.Y. Lee, and S.W. Nam. 2012. HDAC2 overexpression confers oncogenic potential to human lung cancer cells by deregulating expression of apoptosis and cell cycle proteins. Journal of Cellular Biochemistry 113: 2167-2177.
63. Kato, H., S. Tamamizu-Kato, and F. Shibasaki. 2004. Histone deacetylase 7 associates with hypoxia-inducible factor 1alpha and increases transcriptional activity. Journal of Biological Chemistry 279: 41966-41974.
64. Kawai, H., H. Li, S. Avraham, S. Jiang, and H.K. Avraham. 2003. Overexpression of histone deacetylase HDAC1 modulates breast cancer progression by negative regulation of estrogen receptor alpha. International Journal of Cancer 107: 353-358.
65. Kelly, W.K., O.A. O'Connor, L.M. Krug, J.H. Chiao, M. Heaney, T. Curley, B. MacGregore-Cortelli, W. Tong, J.P. Secrist, L. Schwartz, S. Richardson, E. Chu, S. Olgac, P.A. Marks, H. Scher, and V.M. Richon. 2005. Phase I study of an oral histone deacetylase inhibitor, suberoylanilide hydroxamic acid, in patients with advanced cancer. Journal of Clinical Oncology 23: 3923-3931.
66. Khan, N., M. Jeffers, S. Kumar, C. Hackett, F. Boldog, N. Khramtsov, X. Qian, E. Mills, S.C. Berghs, N. Carey, P.W. Finn, L.S. Collins, A. Tumber, J.W. Ritchie, P.B. Jensen, H.S. Lichenstein, and M. Sehested. 2008. Determination of the class and isoform selectivity of small-molecule histone deacetylase inhibitors. Biochemical Journal 409: 581-589.
67. Kim, M.S., H.J. Kwon, Y.M. Lee, J.H. Baek, J.E. Jang, S.W. Lee, E.J. Moon, H.S. Kim, S.K. Lee, H.Y. Chung, C.W. Kim, and K.W. Kim. 2001. Histone deacetylases induce angiogenesis by negative regulation of tumor suppressor genes. Nature Medicine 7: 437-443.
68. Kim, S.H., J.W. Jeong, J.A. Park, J.W. Lee, J.H. Seo, B.K. Jung, M.K. Bae, and K.W. Kim. 2007. Regulation of the HIF-1alpha stability by histone deacetylases. Oncology Reports 17: 647-651.
69. Kim, M.K., Y.J. Kang, D.H. Kim, M.A. Hossain, J.Y. Jang, S.H. Lee, J.H. Yoon, P. Chun, H.R. Moon, H.S. Kim, H.Y. Chung, and N.D. Kim. 2014. A novel hydroxamic acid derivative, MHY218, induces apoptosis and cell cycle arrest through downregulation of NF-κB in HCT116 human colon cancer cells. International Journal of Oncology 44: 256-264.
70. Kirschbaum, M., P. Frankel, L. Popplewell, J. Zain, M. Delioukina, V. Pullarkat, D. Matsuoka, B. Pulone, A.J. Rotter, I. Espinoza-Delgado, A. Nademanee, S.J. Forman, D. Gandara, and E. Newman. 2011. Phase II study of vorinostat for treatment of relapsed or refractory indolent non-Hodgkin's lymphoma and mantle cell lymphoma. Journal of Clinical Oncology 29: 1198-1203.
71. Kong, X., Z. Lin, D. Liang, D. Fath, N. Sang, and J. Caro. 2006. Histone deacetylase inhibitors induce VHL and ubiquitin-independent proteasomal degradation of hypoxia-inducible factor 1alpha. Molecular and Cellular Biology 26: 2019-2028.
72. Konstantinopoulos, P.A., A.J. Wilson, J. Saskowski, E. Wass, and D. Khabele. 2014. Suberoylanilide hydroxamic acid (SAHA) enhances olaparib activity by targeting homologous recombination DNA repair in ovarian cancer. Gynecologic Oncology 133: 599-606.
73. Koprinarova, M., P. Botev, and G. Russev. 2011. Histone deacetylase inhibitor sodium butyrate enhances cellular radiosensitivity by inhibiting both DNA nonhomologous end joining and homologous recombination. DNA Repair (Amsterdam) 10: 970-977.
74. Kouzarides, T. 1999. Histone acetylases and deacetylases in cell proliferation. Current Opinion in Genetics and Development 9: 40-48.
75. Kovacs, J.J., P.J. Murphy, S. Gaillard, X. Zhao, J.T. Wu, C.V. Nicchitta, M. Yoshida, D.O. Toft, W.B. Pratt, and T.P. Yao. 2005. HDAC6 regulates Hsp90 acetylation and chaperone-dependent activation of glucocorticoid receptor. Molecular Cell 18: 601-607.
76. Lassen, U., L.R. Molife, M. Sorensen, S.A. Engelholm, L. Vidal, R. Sinha, R.T. Penson, P. Buhl-Jensen, E. Crowley, J. Tjornelund, P. Knoblauch, and J.S. de Bono. 2010. A phase I study of the safety and pharmacokinetics of the histone deacetylase inhibitor belinostat administered in combination with carboplatin and/or paclitaxel in patients with solid tumours. British Journal of Cancer 103: 12-17.
77. Lee, Y.M., S.H. Kim, H.S. Kim, M. Jin Son, H. Nakajima, H. Jeong Kwon, and K.W. Kim. 2003. Inhibition of hypoxia-induced angiogenesis by FK228, a specific histone deacetylase inhibitor, via suppression of HIF-1alpha activity. Biochemical and Biophysical Research Communications 300: 241-246.
78. Li, D., X. Sun, L. Zhang, B. Yan, S. Xie, R. Liu, M. Liu, and J. Zhou. 2014. Histone deacetylase 6 and cytoplasmic linker protein 170 function together to regulate the motility of pancreatic cancer cells. Protein and Cell 5: 214-223.
79. Lin, R.J., L. Nagy, S. Inoue, W.L. Shao, W.H. Miller, and R.M. Evans. 1998. Role of the histone deacetylase complex in acute promyelocytic leukaemia. Nature 391: 811-814.
80. Luo, J., F. Su, D. Chen, A. Shiloh, and W. Gu. 2000. Deacetylation of p53 modulates its effect on cell growth and apoptosis. Nature 408: 377-381.
81. Luu, T.H., R.J. Morgan, L. Leong, D. Lim, M. McNamara, J. Portnow, P. Frankel, D.D. Smith, J.H. Doroshow, C. Wong, A. Aparicio, D.R. Gandara, and G. Somlo. 2008. A phase II trial of vorinostat (suberoylanilide hydroxamic acid) in metastatic breast cancer: A California Cancer Consortium study. Clinical Cancer Research 14: 7138-7142.
82. Lynch Jr., D.R., J.B. Washam, and L.K. Newby. 2012. QT interval prolongation and torsades de pointes in a patient undergoing treatment with vorinostat: A case report and review of the literature. Cardiology Journal 19: 434-438.
83. Mackay, H.J., H. Hirte, T. Colgan, A. Covens, K. MacAlpine, P. Grenci, L. Wang, J. Mason, P.A. Pham, M.S. Tsao, J. Pan, J. Zwiebel, and A.M. Oza. 2010. Phase II trial of the histone deacetylase inhibitor belinostat in women with platinum resistant epithelial ovarian cancer and micropapillary (LMP) ovarian tumours. European Journal of Cancer 46: 1573-1579.
84. Mal, A., and M.L. Harter. 2003. MyoD is functionally linked to the silencing of a muscle-specific regulatory gene prior to skeletal myogenesis. Proceedings of the National Academy of Sciences of USA 100: 1735-1739.
85. Mal, A., M. Sturniolo, R.L. Schiltz, M.K. Ghosh, and M.L. Harter. 2001. A role for histone deacetylase HDAC1 in modulating the transcriptional activity of MyoD: Inhibition of the myogenic program. EMBO Journal 20: 1735-1739.
86. Mann, B.S., J.R. Johnson, M.H. Cohen, R. Justice, and R. Pazdur. 2007. FDA approval summary: Vorinostat for treatment of advanced primary cutaneous T-cell lymphoma. Oncologist 12: 1247-1252.
87. Marks, P., R.A. Rifkind, V.M. Richon, R. Breslow, T. Miller, and W.K. Kelly. 2001. Histone deacetylases and cancer: Causes and therapies. Nature Reviews Cancer 1: 194-202.
88. Marquard, L., L.M. Gjerdrum, I.J. Christensen, P.B. Jensen, M. Sehested, and E. Ralfkiaer. 2008. Prognostic significance of the therapeutic targets histone deacetylase 1, 2, 6 and acetylated histone H4 in cutaneous T-cell lymphoma. Histopathology 53: 267-277.
89. Martínez-Balbás, M.A., U.M. Bauer, S.J. Nielsen, A. Brehm, and T. Kouzarides. 2000. Regulation of E2F1 activity by acetylation. EMBO Journal 19: 662-671.
90. Milde, T., I. Oehme, A. Korshunov, A. Kopp-Schneider, M. Remke, P. Northcott, H.E. Deubzer, M. Lodrini, M.D. Taylor, A. von Deimling, S. Pfister, and O. Witt. 2010. HDAC5 and HDAC9 in medulloblastoma: Novel markers for risk stratification and role in tumor cell growth. Clinical Cancer Research 16: 3240-3252.
91. Minamiya, Y., T. Ono, H. Saito, N. Takahashi, M. Ito, M. Mitsui, S. Motoyama, and J. Ogawa. 2011. Expression of histone deacetylase 1 correlates with a poor prognosis in patients with adenocarcinoma of the lung. Lung Cancer 74: 300-304.
92. Modesitt, S.C., M. Sill, J.S. Hoffman, D.P. Bender, and Gynecologic Oncology Group. 2008. A phase II study of vorinostat in the treatment of persistent or recurrent epithelial ovarian or primary peritoneal carcinoma: A Gynecologic Oncology Group study. Gynecologic Oncology 109: 182-186.
93. Molife, L.R., G. Attard, P.C. Fong, V. Karavasilis, A.H. Reid, S. Patterson, C.E. Riggs Jr., C. Higano, W.M. Stadler, W. McCulloch, D. Dearnaley, C. Parker, and J.S. de Bono. 2010. Phase II, two-stage, single-arm trial of the histone deacetylase inhibitor (HDACi) romidepsin in metastatic castration-resistant prostate cancer (CRPC). Annals of Oncology 21: 109-113.
94. Montgomery, R.L., C.A. Davis, M.J. Potthoff, M. Haberland, J. Fielitz, X. Qi, J.A. Hill, J.A. Richardson, and E.N. Olson. 2007. Histone deacetylases 1 and 2 redundantly regulate cardiac morphogenesis, growth, and contractility. Genes and Development 21: 1790-1802.
95. Moreno, D.A., C.A. Scrideli, M.A. Cortez, R. de Paula Queiroz, E.T. Valera, V. da Silva Silveira, J.A. Yunes, S.R. Brandalise, and L.G. Tone. 2010. Differential expression of HDAC3, HDAC7 and HDAC9 is associated with prognosis and survival in childhood acute lymphoblastic leukaemia. British Journal of Haematology 150: 665-673.
96. Müller, B.M., L. Jana, A. Kasajima, A. Lehmann, J. Prinzler, J. Budczies, K.J. Winzer, M. Dietel, W. Weichert, and C. Denkert. 2013. Differential expression of histone deacetylases HDAC1, 2 and 3 in human breast cancer - Overexpression of HDAC2 and HDAC3 is associated with clinicopathological indicators of disease progression. BMC Cancer 13: 215.
97. Munshi, A., J.F. Kurland, T. Nishikawa, T. Tanaka, M.L. Hobbs, S.L. Tucker, S. Ismail, C. Stevens, and R.E. Meyn. 2005. Histone deacetylase inhibitors radiosensitize human melanoma cells by suppressing DNA repair activity. Clinical Cancer Research 11: 4912-4922.
98. Mwakwari, S.C., V. Patil, W. Guerrant, and A.K. Oyelere. 2010. Macrocyclic histone deacetylase inhibitors. Current Topics in Medicinal Chemistry 10: 1423-1440.
99. Noh, E.J., D.S. Lim, G. Jeong, and J.S. Lee. 2009. An HDAC inhibitor, trichostatin A, induces a delay at G2/M transition, slippage of spindle checkpoint, and cell death in a transcription-dependent manner. Biochemical and Biophysical Research Communications 378: 326-331.
100. Norton, V.G., B.S. Imai, P. Yau, and E.M. Bradbury. 1989. Histone acetylation reduces nucleosome core particle linking number change. Cell 57: 449-457.
101. Oehme, I., H.E. Deubzer, D. Wegener, D. Pickert, J.P. Linke, B. Hero, A. Kopp-Schneider, F. Westermann, S.M. Ulrich, A. von Deimling, M. Fischer, and O. Witt. 2009. Histone deacetylase 8 in neuroblastoma tumorigenesis. Clinical Cancer Research 15: 91-99.
102. Ogura, M., K. Ando, T. Suzuki, K. Ishizawa, S.Y. Oh, K. Itoh, K. Yamamoto, W.Y. Au, H.F. Tien, Y. Matsuno, T. Terauchi, K. Yamamoto, M. Mori, Y. Tanaka, T. Shimamoto, K. Tobinai, and W.S. Kim. 2014. A multicentre phase II study of vorinostat in patients with relapsed or refractory indolent B-cell non-Hodgkin lymphoma and mantle cell lymphoma. British Journal of Haematology 165: 768-776.
103. Olsen, E.A., Y.H. Kim, T.M. Kuzel, T.R. Pacheco, F.M. Foss, S. Parker, S.R. Frankel, C. Chen, J.L. Ricker, J.M. Arduino, and M. Duvic. 2007. Phase IIb multicenter trial of vorinostat in patients with persistent, progressive, or treatment refractory cutaneous T-cell lymphoma. Journal of Clinical Oncology 25: 3109-3115.
104. Osada, H., Y. Tatematsu, H. Saito, Y. Yatabe, T. Mitsudomi, and T. Takahashi. 2004. Reduced expression of class II histone deacetylase genes is associated with poor prognosis in lung cancer patients. International Journal of Cancer 112: 26-32.
105. Otterson, G.A., L. Hodgson, H. Pang, E.E. Vokes, and Cancer and Leukemia Group B. 2010. Phase II study of the histone deacetylase inhibitor Romidepsin in relapsed small cell lung cancer (Cancer and Leukemia Group B 30304). Journal of Thoracic Oncology 5: 1644-1648.
106. Ouaïssi, M., I. Sielezneff, R. Silvestre, B. Sastre, J.P. Bernard, J.S. Lafontaine, M.J. Payan, L. Dahan, N. Pirrò, J.F. Seitz, E. Mas, D. Lombardo, and A. Ouaissi. 2008. High histone deacetylase 7 (HDAC7) expression is significantly associated with adenocarcinomas of the pancreas. Annals of Surgical Oncology 15: 2318-2328.
107. Ozawa, Y., M. Towatari, S. Tsuzuki, F. Hayakawa, T. Maeda, Y. Miyata, M. Tanimoto, and H. Saito. 2001. Histone deacetylase 3 associates with and represses the transcription factor GATA-2. Blood 98: 2116-2123.
108. Park, S.Y., J.A. Jun, K.J. Jeong, H.J. Heo, J.S. Sohn, H.Y. Lee, C.G. Park, and J. Kang. 2011. Histone deacetylases 1, 6 and 8 are critical for invasion in breast cancer. Oncology Reports 25: 1677-1681.
109. Peart, M.J., G.K. Smyth, R.K. van Laar, D.D. Bowtell, V.M. Richon, P.A. Marks, A.J. Holloway, and R.W. Johnstone. 2005. Identification and functional significance of genes regulated by structurally different histone deacetylase inhibitors. Proceedings of the National Academy of Sciences of USA 102: 3697-3702.
110. Pérez-Perarnau, A., L. Coll-Mulet, C. Rubio-Patiño, D. Iglesias-Serret, A.M. Cosialls, D.M. González-Gironès, M. de Frias, A.F. de Sevilla, E. de la Banda, G. Pons, and J. Gil. 2011. Analysis of apoptosis regulatory genes altered by histone deacetylase inhibitors in chronic lymphocytic leukemia cells. Epigenetics 6: 1228-1235.
111. Piekarz, R.L., A.R. Frye, J.J. Wright, S.M. Steinberg, D.J. Liewehr, D.R. Rosing, V. Sachdev, T. Fojo, and S.E. Bates. 2006. Cardiac studies in patients treated with depsipeptide, FK228, in a phase II trial for T-cell lymphoma. Clinical Cancer Research 12: 3762-3773.
112. Piekarz, R.L., R. Frye, M. Turner, J.J. Wright, S.L. Allen, M.H. Kirschbaum, J. Zain, H.M. Prince, J.P. Leonard, L.J. Geskin, C. Reeder, D. Joske, W.D. Figg, E.R. Gardner, S.M. Steinberg, E.S. Jaffe, M. Stetler-Stevenson, S. Lade, A.T. Fojo, and S.E. Bates. 2009. Phase II multi-institutional trial of the histone deacetylase inhibitor romidepsin as monotherapy for patients with cutaneous T-cell lymphoma. Journal of Clinical Oncology 27: 5410-5417.
113. Qian, D.Z., S.K. Kachhap, S.J. Collis, H.M. Verheul, M.A. Carducci, P. Atadja, and R. Pili. 2006. Class II histone deacetylases are associated with VHL-independent regulation of hypoxia-inducible factor 1 alpha. Cancer Research 66: 8814-8821.
114. Qiu, L., A. Burgess, D.P. Fairlie, H. Leonard, P.G. Parsons, and B.G. Gabrielli. 2000. Histone deacetylase inhibitors trigger a G2 checkpoint in normal cells that is defective in tumor cells. Molecular Biology of the Cell 11: 2069-2083.
115. Quint, K., A. Agaimy, P. Di Fazio, R. Montalbano, C. Steindorf, R. Jung, C. Hellerbrand, A. Hartmann, H. Sitter, D. Neureiter, and M. Ocker. 2011. Clinical significance of histone deacetylases 1, 2, 3, and 7: HDAC2 is an independent predictor of survival in HCC. Virchows Archives 459: 129-139.
116. Ramalingam, S.S., C.P. Belani, C. Ruel, P. Frankel, B. Gitlitz, M. Koczywas, I. Espinoza-Delgado, and D. Gandara. 2009. Phase II study of belinostat (PXD101), a histone deacetylase inhibitor, for second line therapy of advanced malignant pleural mesothelioma. Journal of Thoracic Oncology 4: 97-101.
117. Richon, V.M., Y. Webb, R. Merger, T. Sheppard, B. Jursic, L. Ngo, F. Civoli, R. Breslow, R.A. Rifkind, and P.A. Marks. 1996. Second generation hybrid polar compounds are potent inducers of transformed cell differentiation. Proceedings of the National Academy of Sciences of USA 93: 5705-5708.
118. Richon, V.M., T.W. Sandhoff, R.A. Rifkind, and P.A. Marks. 2000. Histone deacetylase inhibitor selectively induces p21WAF1 expression and gene-associated histone acetylation. Proceedings of the National Academy of Sciences of USA 97: 10014-10019.
119. Ropero, S., and M. Esteller. 2007. The role of histone deacetylases (HDACs) in human cancer. Molecular Oncology 1: 19-25.
120. Ropero, S., M.F. Fraga, E. Ballestar, R. Hamelin, H. Yamamoto, M. Boix-Chornet, R. Caballero, M. Alaminos, F. Setien, M.F. Paz, M. Herranz, J. Palacios, D. Arango, T.F. Orntoft, L.A. Aaltonen, S. Schwartz Jr., and M. Esteller. 2006. A truncating mutation of HDAC2 in human cancers confers resistance to histone deacetylase inhibition. Nature Genetics 38: 566-569.
121. Rosato, R.R., and S. Grant. 2005. Histone deacetylase inhibitors: Insights into mechanisms of lethality. Expert Opinion on Therapeutic Targets 9: 809-924.
122. Ruefli, A.A., M.J. Ausserlechner, D. Bernhard, V.R. Sutton, K.M. Tainton, R. Kofler, M.J. Smyth, and R.W. Johnstone. 2001. The histone deacetylase inhibitor and chemotherapeutic agent suberoylanilide hydroxamic acid (SAHA) induces a cell-death pathway characterized by cleavage of Bid and production of reactive oxygen species. Proceedings of the National Academy of Sciences of USA 98: 10833-10838.
123. Sandor, V., A. Senderowicz, S. Mertins, D. Sackett, E. Sausville, M.V. Blagosklonny, and S.E. Bates. 2000. P21-dependent g(1)arrest with downregulation of cyclin D1 and upregulation of cyclin E by the histone deacetylase inhibitor FR901228. British Journal of Cancer 83: 817-825.
124. Sawa, H., H. Murakami, Y. Ohshima, T. Sugino, T. Nakajyo, T. Kisanuki, Y. Tamura, A. Satone, W. Ide, I. Hashimoto, and H. Kamada. 2001. Histone deacetylase inhibitors such as sodium butyrate and trichostatin A induce apoptosis through an increase of the Bcl-2-related protein Bad. Brain Tumor Pathology 18: 109-114.
125. Seo, S.Y. 2012. Multi-targeted hybrids based on HDAC inhibitors for anti-cancer drug discovery. Archives of Pharmacal Research 35: 197-200.
126. Serrador, J.M., J.R. Cabrero, D. Sancho, M. Mittelbrunn, A. Urzainqui, and F. Sánchez-Madrid. 2004. HDAC6 deacetylase activity links the tubulin cytoskeleton with immune synapse organization. Immunity 20: 417-428.
127. Shah, M.H., P. Binkley, K. Chan, J. Xiao, D. Arbogast, M. Collamore, Y. Farra, D. Young, and M. Grever. 2006. Cardiotoxicity of histone deacetylase inhibitor depsipeptide in patients with metastatic neuroendocrine tumors. Clinical Cancer Research 12: 3997-4003.
128. Song, J., J.H. Noh, J.H. Lee, J.W. Eun, Y.M. Ahn, S.Y. Kim, S.H. Lee, W.S. Park, N.J. Yoo, J.Y. Lee, and S.W. Nam. 2005. Increased expression of histone deacetylase 2 is found in human gastric cancer. APMIS 113: 264-268.
129. Stadler, W.M., K. Margolin, S. Ferber, W. McCulloch, and J.A. Thompson. 2006. A phase II study of depsipeptide in refractory metastatic renal cell cancer. Clinical Genitourinary Cancer 5: 57-60.
130. Steele, N.L., J.A. Plumb, L. Vidal, J. Tjørnelund, P. Knoblauch, A. Rasmussen, C.E. Ooi, P. Buhl-Jensen, R. Brown, T.R. Evans, and J.S. DeBono. 2008. A phase 1 pharmacokinetic and pharmacodynamic study of the histone deacetylase inhibitor belinostat in patients with advanced solid tumors. Clinical Cancer Research 14: 804-810.
131. Straus, S.M., J.A. Kors, M.L. De Bruin, C.S. van der Hooft, A. Hofman, J. Heeringa, J.W. Deckers, J.H. Kingma, M.C. Sturkenboom, B.H. Stricker, and J.C. Witteman. 2006. Prolonged QTc interval and risk of sudden cardiac death in a population of older adults. Journal of the American College of Cardiology 47: 362-367.
132. Strevel, E.L., D.J. Ing, and L.L. Siu. 2007. Molecularly targeted oncology therapeutics and prolongation of the QT interval. Journal of Clinical Oncology 25: 3362-3371.
133. Stypula-Cyrus, Y., D. Damania, D.P. Kunte, M.D. Cruz, H. Subramanian, H.K. Roy, and V. Backman. 2013. HDAC up-regulation in early colon field carcinogenesis is involved in cell tumorigenicity through regulation of chromatin structure. PLoS ONE 8: e64600.
134. Sutheesophon, K., N. Nishimura, Y. Kobayashi, Y. Furukawa, M. Kawano, K. Itoh, Y. Kano, H. Ishii, and Y. Furukawa. 2005. Involvement of the tumor necrosis factor (TNF)/TNF receptor system in leukemic cell apoptosis induced by histone deacetylase inhibitor depsipeptide (FK228). Journal of Cellular Physiology 203: 387-397.
135. Traynor, A.M., S. Dubey, J.C. Eickhoff, J.M. Kolesar, K. Schell, M.S. Huie, D.L. Groteluschen, S.M. Marcotte, C.M. Hallahan, H.R. Weeks, G. Wilding, I. Espinoza-Delgado, and J.H. Schiller. 2009. Vorinostat (NSC# 701852) in patients with relapsed non-small cell lung cancer: A Wisconsin Oncology Network phase II study. Journal of Thoracic Oncology 4: 522-526.
136. Ungerstedt, J.S., Y. Sowa, W.S. Xu, Y. Shao, M. Dokmanovic, G. Perez, L. Ngo, A. Holmgren, X. Jiang, and P.A. Marks. 2005. Role of thioredoxin in the response of normal and transformed cells to histone deacetylase inhibitors. Proceedings of the National Academy of Sciences of USA 102: 673-678.
137. U.S. Food and Drug Administration. Drugs. Belinostat. http://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm403960.htm. Accessed 21 Nov 2014.
138. U.S. Food and Drug Administration. Drugs. Romidepsin. http://www.fda.gov/AboutFDA/CentersOffices/OfficeofMedicalProductsandTobacco/CDER/ucm189466.htm. Accessed 21 Nov 2014.
139. Vansteenkiste, J., E. Van Cutsem, H. Dumez, C. Chen, J.L. Ricker, S.S. Randolph, and P. Schöffski. 2008. Early phase II trial of oral vorinostat in relapsed or refractory breast, colorectal, or non-small cell lung cancer. Investigational New Drugs 26: 483-488.
140. Verdin, E., F. Dequiedt, and H.G. Kasler. 2003. Class II histone deacetylases: Versatile regulators. Trends in Genetics 19: 286-293.
141. Wang, J.C., M.I. Kafeel, B. Avezbakiyev, C. Chen, Y. Sun, C. Rathnasabapathy, M. Kalavar, Z. He, J. Burton, and S. Lichter. 2011. Histone deacetylase in chronic lymphocytic leukemia. Oncology 81: 325-329.
142. Watamoto, K., M. Towatari, Y. Ozawa, Y. Miyata, M. Okamoto, A. Abe, T. Naoe, and H. Saito. 2003. Altered interaction of HDAC5 with GATA-1 during MEL cell differentiation. Oncogene 22: 9176-9184.
143. Weichert, W., A. Röske, V. Gekeler, T. Beckers, M.P. Ebert, M. Pross, M. Dietel, C. Denkert, and C. Röcken. 2008a. Association of patterns of class I histone deacetylase expression with patient prognosis in gastric cancer: A retrospective analysis. Lancet Oncology 9: 139-148.
144. Weichert, W., A. Roske, S. Niesporek, A. Noske, A.C. Buckendahl, M. Dietel, V. Gekeler, M. Boehm, T. Beckers, and C. Denkert. 2008b. Class I histone deacetylase expression has independent prognostic impact in human colorectal cancer: Specific role of class I histone deacetylases in vitro and in vivo. Clinical Cancer Research 14: 1669-1677.
145. Weichert, W., A. Röske, V. Gekeler, T. Beckers, C. Stephan, K. Jung, F.R. Fritzsche, S. Niesporek, C. Denkert, M. Dietel, and G. Kristiansen. 2008c. Histone deacetylases 1, 2 and 3 are highly expressed in prostate cancer and HDAC2 expression is associated with shorter PSA relapse time after radical prostatectomy. British Journal of Cancer 98: 604-610.
146. Whitehead, R.P., C. Rankin, P.M. Hoff, P.J. Gold, K.G. Billingsley, R.A. Chapman, L. Wong, J.H. Ward, J.L. Abbruzzese, and C.D. Blanke. 2009. Phase II trial of romidepsin (NSC-630176) in previously treated colorectal cancer patients with advanced disease: A Southwest Oncology Group study (S0336). Investigational New Drugs 27: 469-475.
147. Whittaker, S.J., M.F. Demierre, E.J. Kim, A.H. Rook, A. Lerner, M. Duvic, J. Scarisbrick, S. Reddy, T. Robak, J.C. Becker, A. Samtsov, W. McCulloch, and Y.H. Kim. 2010. Final results from a multicenter, international, pivotal study of romidepsin in refractory cutaneous T-cell lymphoma. Journal of Clinical Oncology 28: 4485-4491.
148. Wolbrette, D. 2004. Drugs that cause torsades de pointes and increase the risk of sudden cardiac death. Current Cardiology Reports 6: 379-384.
149. Xie, H.J., J.H. Noh, J.K. Kim, K.H. Jung, J.W. Eun, H.J. Bae, M.G. Kim, Y.G. Chang, J.Y. Lee, H. Park, and S.W. Nam. 2012. HDAC1 inactivation induces mitotic defect and caspase independent autophagic cell death in liver cancer. PLoS ONE 7: e34265.
150. Yang, W.M., Y.L. Yao, J.M. Sun, J.R. Davie, and E. Seto. 1997. Isolation and characterization of cDNAs corresponding to an additional member of the human histone deacetylase gene family. Journal of Biological Chemistry 272: 28001-28007.
151. Yamashita, Y., M. Shimada, N. Harimoto, T. Rikimaru, K. Shirabe, S. Tanaka, and K. Sugimachi. 2003. Histone deacetylase inhibitor trichostatin A induces cell-cycle arrest/apoptosis and hepatocyte differentiation in human hepatoma cells. International Journal of Cancer 103: 572-576.
152. Younes, A., Y. Oki, R.G. Bociek, J. Kuruvilla, M. Fanale, S. Neelapu, A. Copeland, H. Zhou, S. Jiang, J. Chen, and S.B. Su. 2014. Suberoylanilide hydroxamic acid suppresses inflammation-induced neovascularization. Canadian Journal of Physiology and Pharmacology 92: 879-885.
153. Yuan, Z.L., Y.J. Guan, D. Chatterjee, and Y.E. Chin. 2005. STAT3 dimerization regulated by reversible acetylation of a single lysine residue. Science 307: 269-273.
154. Zgouras, D., A. Wächtershäuser, D. Frings, and J. Stein. 2003. Butyrate impairs intestinal tumor cell-induced angiogenesis by inhibiting HIF-1alpha nuclear translocation. Biochemical and Biophysical Research Communications 300(4): 832-838.
155. Zhang, X.D., S.K. Gillespie, J.M. Borrow, and P. Hersey. 2004. The histone deacetylase inhibitor suberic bishydroxamate regulates the expression of multiple apoptotic mediators and induces mitochondria-dependent apoptosis of melanoma cells. Molecular Cancer Therapeutics 3: 425-435.
156. Zhang, Y., M. Adachi, R. Kawamura, and K. Imai. 2006. Bmf is a possible mediator in histone deacetylase inhibitors FK228 and CBHA-induced apoptosis. Cell Death and Differentiation 13: 129-140.
157. Zhao, Y., J. Tan, L. Zhuang, X. Jiang, E.T. Liu, and Q. Yu. 2005. Inhibitors of histone deacetylases target the Rb-E2F1 pathway for apoptosis induction through activation of proapoptotic protein Bim. Proceedings of the National Academy of Sciences of USA 102: 16090-16095.
158. Zheng, G., and Y.C. Yang. 2005. Sumoylation and acetylation play opposite roles in the transactivation of PLAG1 and PLAGL2. Journal of Biological Chemistry 280: 40773-40781.
159. Zhou, H., S. Jiang, J. Chen, and S.B. Su. 2014. Suberoylanilide hydroxamic acid suppresses inflammation-induced neovascularization. Canadian Journal of Physiology and Pharmacology 92: 879-885.